Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study
Sabina A. Guler, Lukas Ebner, Catherine Beigelman‐Aubry et al. · European Respiratory Journal · 2021
Background The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing global healthcare challenge. Up to one-third of hospitalised patients develop severe pulmonary complications and acute respiratory distress syndrome. Pulmonary outcomes following COVID-19 are unknown. Methods The Swiss COVID-19 lung study is a multicentre prospective cohort investigating pulmonary sequelae of COVID-19. We report on initial follow-up 4 months after mild/moderate or severe/critical COVID-19 according to the World Health Organization severity classification. Results 113 COVID-19 survivors were included (mild/moderate n=47, severe/critical n=66). We confirmed several comorbidities as risk factors for severe/critical disease. Severe/critical disease was associated with impaired pulmonary function, i.e. diffusing capacity of the lung for carbon monoxide ( D LCO ) % predicted, reduced 6-min walk distance (6MWD) and exercise-induced oxygen desaturation. After adjustment for potential confounding by age, sex and body mass index (BMI), patients after severe/critical COVID-19 had a D LCO 20.9% pred (95% CI 12.4–29.4% pred, p=0.01) lower at follow-up. D LCO % pred was the strongest independent factor associated with previous severe/critical disease when age, sex, BMI, 6MWD and minimal peripheral oxygen saturation at exercise were included in the multivariable model (adjusted odds ratio per 10% predicted 0.59, 95% CI 0. 37–0.87; p=0.01). Mosaic hypoattenuation on chest computed tomography at follow-up was significantly associated with previous severe/critical COVID-19 including adjustment for age and sex (adjusted OR 11.7, 95% CI 1.7–239; p=0.03). Conclusions 4 months after severe acute respiratory syndrome coronavirus 2 infection, severe/critical COVID-19 was associated with significant functional and radiological abnormalities, potentially due to small-airway and lung parenchymal disease. A systematic follow-up for survivors needs to be evaluated to optimise care for patients recovering from COVID-19.
Cited by 407 works. doi:10.1183/13993003.03690-2020 Open-access PDF
Authors
- Sabina A. Guler
- Lukas Ebner
- Catherine Beigelman‐Aubry
- Pierre‐Olivier Bridevaux
- Martin Hugo Brutsche
- Christian Friedrich Clarenbach
- Christian Garzoni
- Thomas Geiser
- Alexandra Lenoir
- Marco Mancinetti
- Bruno Naccini
- Sebastian R. Ott
- Lise Piquilloud
- Maura Prella
- Yok‐Ai Que
- Paula M. Soccal
- Christophe von Garnier
- Manuela Funke-Chambour
References
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- SARS and MERS: recent insights into emerging coronaviruses
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
- Functional Disability 5 Years after Acute Respiratory Distress Syndrome
- Standardisation of the measurement of lung volumes
- Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement
- ATS/ERS Statement on Respiratory Muscle Testing
- An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease
- Pulmonary pathology of severe acute respiratory syndrome in Toronto